All posts related to "patient input"

Let BC PharmaCare hear “Your Voice” on secukinumab

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis

Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about secukinumab for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.

The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
Continue reading

Call for patient input on SEB etanercept for RA and AS

Stickman with megaphone calling for patient input

Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.

Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading

Demande de rétroaction de patients sur le secukinumab (Cosentyx®) dans le traitement de la spondylarthrite ankylosante et de l’arthrite psoriasique

Megaphone GraphicSouffrez-vous de spondylarthrite ankylosante ou d’arthrite psoriasique ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Le Programme commun d’évaluation des médicaments (PCEM) invite actuellement les patients et leurs fournisseurs de soins à faire parvenir aux organismes représentant les patients leurs suggestions et commentaires sur la présentation par le fabricant du secukinumab (Cosentyx®) dans le traitement de la spondylarthrite ankylosante et de l’arthrite psoriasique. Le secukinumab est un anticorps monoclonal entièrement humain qui cible l’action de l’interleukine 17A (IL-17A), une protéine au cœur du développement des maladies inflammatoires. Le secukinumab est administré par injection.

Faisant partie de l’Agence canadienne des médicaments et des technologies de la santé, le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.

Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). Nous souhaitons recueillir les commentaires de nos membres, nos abonnés et les membres de leur famille atteints de spondylarthrite ankylosante ou d’arthrite psoriasique. Les fournisseurs de soins sont également invités à nous faire parvenir leurs commentaires.

Nous désirons communiquer votre point de vue au PCEM. Continue reading

Call for patient input on secukinumab for AS and PsA

Megaphone GraphicDo you have ankylosing spondylitis (AS) or psoriatic arthritis (PsA) or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (Cosentyx®) for the treatment of ankylosing spondylitis or psoriatic arthritis. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We are calling for input from our members, subscribers and their family members who have ankylosing spondylitis or psoriatic arthritis. Caregivers are also invited to provide input.

We would like to gather your views and share them with the CDR.  Continue reading

What has ACE done for you lately?

Nov 2015 SignageHere’s what we’ve been working on this Fall

Canada’s Best Workplaces for Employees Living with Arthritis

Congratulations to Simon Fraser University, L’Oréal Canada and High Liner Foods for winning the 2015 Canada’s Best Workplaces for Employees Living with Arthritis award.
Here are some best practices identified during our interview process: Continue reading

CADTH’s Request for Advice on the CDEC’s recommendations for denosumab

Stickman with megaphone calling for patient inputWould you like to provide input to inform CADTH’s report and CDEC’s advice? 

The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.

CADTH is interested in learning:

  1. How should fracture risk be best described?
  2. Is there a place for age (>75 years) or bone density scores, or are these adequately captured within fracture risk?
  3. How should bisphosphonate failure be best described?
  4. How should bisphosphonate intolerance be best described?

Advice is sought regarding the alignment of the CDEC recommendations for women (2011) and for men (2015).   Continue reading